Deal snapshot: MEREO BIOPHARMA TO LICENSE ASTRAZENECA DRUG, WITH OPTION TO BUY.
UK-based biopharmaceutical company Mereo BioPharma Group plc (AIM: MPH) has reached an agreement with UK-based drugmaker AstraZeneca (NYSE: AZN) for an exclusive license, including an option to acquire, AZD9668, an oral inhibitor of neutrophil elastase, the company said on Monday.
Under the exclusive license the company plans to conduct a Phase II study for the treatment of alpha-1 antitrypsin deficiency, a congenital orphan condition. The company has the right to exercise its option to acquire AZD9668 after the initiation of pivotal studies.
Target: Exclusive license to AZD9668, an oral inhibitor of neutrophil elastase
Buyer: Mereo BioPharma
Deal size in USD: 5m
Type: Corporate Acquisition
Financing: Cash and Stock
Buyer advisor: , ,
Comment: Deal includes option to buy
|Printer friendly Cite/link Email Feedback|
|Publication:||M & A Navigator|
|Date:||Oct 30, 2017|
|Previous Article:||Deal snapshot: TEKCAPITAL ACQUIRES PATENTED AL VALET SYSTEM FROM FLORIDA, US UNIVERSITY.|
|Next Article:||Deal snapshot: KEYWORDS STUDIOS CLOSES USD 66.4M ACQUISITION OF VMC CONSULTING, VOLT CANADA.|